Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Leidos Holdings (NYSE:LDOS) Rides a Wave of Defense Demand

● Leidos reported record second-quarter 2026Revenueof about $4.56 billion, up 7% year over year, and raised its full-year 2026 guidance.

Nitish Kishor | 31 August 2026

Bolt Biotherapeutics (NASDAQ:BOLT) Slides as the Market Awaits a Key Data Readout

● Bolt Biotherapeutics reported a second-quarter 2026 net loss of about $7.7 million and held about $18.1 million in cash, expected to fund operations into early 2027.

Nitish Kishor | 31 August 2026

Salesforce (NYSE:CRM) Draws Fresh Attention as Its AI Business Scales

● Salesforce reported fiscal second-quarter 2027 totalRevenueof about $11.3 billion, up 11% year over year, with subscription and support revenue up 12%.

Nitish Kishor | 31 August 2026

Deckers Outdoor (NYSE:DECK) Keeps Building Quietly on Two Strong Brands

● Deckers reported record fiscal first-quarter 2027 net sales of about $1.020 billion, up 5.7% year over year, with HOKA up 7.7% and UGG up 4.9%.

Nitish Kishor | 31 August 2026

Digimarc (NASDAQ:DMRC) Is Under Pressure: What Would It Take to Turn the Story Around?

● Digimarc reported second-quarter 2026Revenueof about $7.4 million, down roughly 7% year over year, with annualRecurring Revenuealso declining.

Nitish Kishor | 31 August 2026

Driven Brands Holdings (NASDAQ:DRVN) Loses Ground Despite Rejecting a Buyout Bid

● Driven Brands reported second-quarter 2026Revenueof about $507.4 million, up about 7% year over year, withNet Incomeof about $37.3 million.

Nitish Kishor | 31 August 2026

Accenture (NYSE:ACN) Firms Up as the Market Weighs AI Demand Against Booking Softness

● Accenture reported fiscal third-quarter 2026Revenueof about $18.7 billion, up 6% in U.S. dollars, withGAAPdiluted EPS of $3.80, up 9%.

Nitish Kishor | 31 August 2026

Aptevo Therapeutics (NASDAQ:APVO) Cools Despite Striking Early Trial Results

● Aptevo reported a clinical benefit rate of about 87% and a remission rate of about 81% in its RAINIER trial of mipletamig for frontline AML.

Nitish Kishor | 31 August 2026

Is HeartBeam's (NASDAQ:BEAT) Pullback a Warning or a Contrarian Setup?

● HeartBeam received FDA clearance for its cable-free, synthesized 12-lead ECG technology and is moving toward a U.S. commercial launch.

Nitish Kishor | 31 August 2026

Badger Meter (NYSE:BMI) Slips Even as Wall Street Stays Bullish

● Badger Meter reported second-quarter 2026Revenueof about $222.3 million, topping estimates with sequential gains.

Nitish Kishor | 31 August 2026
Support

Hi! How can we help you today?

Loading…